CJC-1295
Long-Acting GHRH Analogue Studied for Sustained Growth Hormone Pulses
Written by
Dr. Elena Rostova · Ph.D. Biochemistry
Medical review
Dr. Marcus Vance · PharmD, RPh
Last reviewed
August 15, 2026
About the Author
Dr. Elena Rostova · Ph.D. Biochemistry
Lead Research Scientist & Science Editor
Molecular biochemist and peptide researcher with expertise in solid-phase peptide synthesis (SPPS), HPLC purity verification, and mass spectrometry characterization. Directs literature compilation and scientific dossier synthesis at BioPeptide.
About the Reviewer
Dr. Marcus Vance · PharmD, RPh
Medical & Pharmacology Reviewer
Clinical pharmacist and pharmacokinetics consultant specializing in peptide pharmacology, receptor signaling, and preclinical safety data. Focuses on rigorous evaluation of published biochemical literature, receptor kinetics, and study methodology.
Overview
CJC-1295 is a modified analogue of growth-hormone-releasing hormone (GHRH), engineered to resist rapid enzymatic breakdown. It is studied for its potential to extend the duration of natural growth-hormone pulses released by the pituitary gland, and is often examined in research alongside ghrelin-receptor agonists such as Ipamorelin.
Proposed Mechanism
GHRH analogues like CJC-1295 are designed to bind GHRH receptors on the pituitary gland, prompting growth-hormone release in a manner intended to mirror — and in some formulations extend — the body's natural secretion rhythm. Some variants incorporate a Drug Affinity Complex (DAC) that researchers have studied for its effect on the peptide's circulating half-life.
Research Highlights
- Pharmacokinetic studies have compared the half-life and GH-release duration of DAC and non-DAC formulations
- Animal and in-vitro research has examined downstream effects on insulin-like growth factor 1 (IGF-1) levels following administration
- Published studies have investigated combined-administration protocols pairing GHRH analogues with ghrelin-receptor agonists to assess synergistic effects on GH-pulse amplitude
Research Dosing Reference
Rodent pituitary-axis studies
DAC-modified variants are studied on substantially different schedules than non-modified forms due to differing half-lives
Microgram-scale, subcutaneous — frequency depends on DAC vs. non-DAC formulation
Figures above are reported ranges from published animal/laboratory studies, summarized for academic reference — not recommendations for human or animal administration.
Reported Research Cycle Lengths
Reference guides commonly cite cycles of roughly 8 to 12 weeks for CJC-1295 — both the standard (no-DAC / Mod GRF) form, valued for short natural GH pulses, and the DAC-extended form, valued for sustained elevation — typically grouped with other GHRH-analogue literature.
Durations referenced here reflect ranges commonly cited across compound literature and reference guides — summarized for academic comparison only. They are not usage recommendations for humans or animals, and do not substitute for primary source review.
Reconstitution & Volume Calculator
A unit-conversion utility for laboratory use. It converts a vial strength and reconstitution volume into a draw volume — it performs arithmetic only and does not suggest, recommend, or imply an appropriate amount of CJC-1295 for any purpose.
Concentration
2500.0 mcg/mL
Draw volume
0.100 mL
Syringe reading
10.0 units
For laboratory research reference only — not medical advice, and not a dosing recommendation for human or animal use. "Syringe reading" assumes a standard U-100 (100 units per mL) insulin syringe.
Safety & Compliance Notes
- CJC-1295 has not received regulatory approval for human use and remains an investigational research compound
- Dosing figures reflect ranges discussed in published pharmacology literature, not usage instructions
- For in-vitro and animal research applications only
Primary Research Citations
Directly indexed peer-reviewed studies supporting this compound profile
Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA · Journal of Clinical Endocrinology & Metabolism (2006)
PMID: 16352683Jette L, Legault R, Titus L, Castaigne JP, Frohman LA · Endocrinology (2005)
PMID: 15998693Ionescu M, Frohman LA · Journal of Clinical Endocrinology & Metabolism (2006)
PMID: 17090623
Research Grade · >99% HPLC Verified
Order research-grade CJC-1295with batch-specific Certificate of Analysis (COA). Synthesized to >99% purity. Orders are typically processed within 1–3 business days of payment confirmation.
This page is provided for educational and research-reference purposes only and does not constitute medical advice, a treatment recommendation, or an endorsement of human use. Always consult primary peer-reviewed literature and a qualified professional before drawing conclusions about any compound. All products referenced are sold strictly for laboratory research — not for human consumption.